Abstract
With the availability of increasing numbers of targeted monoclonal therapies, the determination of patients who are eligible for a given therapy is critical. One of the best studied examples is the use of trastuzumab, an anti-HER2 therapy, in breast cancer. With the publication of the results of the trial of Trastuzumab in Gastric Cancer (ToGA) and the subsequent FDA approval of trastuzumab for use in gastric and gastroesophageal junction adenocarcinoma, assessment of HER2 status in these upper GI malignancies has become crucial. This chapter will review the current status of HER2 testing in both breast and gastric adenocarcinoma.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Koeppen HK, Wright BD, Burt AD, Quirke P, McNicol AM, Dybdal NO, Sliwkowski MX, Hillan KJ (2001) Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 38(2):96–104
Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM (2000) c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 18(11):2201–2209
Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J (2005) Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16(2):273–278
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, PatonV, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med. 344(11):783–792
Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145, 344(11):783–792
Wolff AC, Hammond ME, Hicks DG, American Society of Clinical Oncology/College of American Pathologists et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013
Hofmann M, Stoss O, Shi D et al (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52(7):797–805. doi:10.1111/j.1365-2559.2008.03028.x, Epub 2008 Apr 18
Rüschoff J, Dietel M, Baretton G et al (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457(3):299–307. doi:10.1007/s00428-010-0952-2, Epub 2010 Jul 28
Hicks D, Whitney-Miller C (2013) The evolving role of HER2 evaluation for diagnosis and clinical decision making for breast and gastric adenocarcinoma. Biotech Histochem 88(3–4):121–131, Epub 2013 Jan 7
Lunt M, Hicks D, Whitney-Miller C (2012) Gastric and gastro-esophageal adenocarcinoma: emerging therapeutic options and diagnostic testing challenges related to HER2. J Oncopathol 1(2):39–45
Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25(5):637–650. doi:10.1038/modpathol.2011.198, Epub 2012 Jan 6, PubMed PMID: 22222640
Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG, Jenkins RB, Persons DL, Tubbs RR, Elizabeth M, Hammond H (2009) Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 133(4):611–612
Hanna WM, Rüschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G (2014) HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol 27(1):4–18
Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917
Bang YJ, Van Cutsem E, Feyereislova A, ToGA Trial Investigators et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Lunt, M.D., Whitney-Miller, C.L. (2014). Adapting HER2 Testing for a Different Organ: New Wine in Old Wineskins. In: Potts, S., Eberhard, D., Wharton, Jr., K. (eds) Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/7653_2014_23
Download citation
DOI: https://doi.org/10.1007/7653_2014_23
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2680-0
Online ISBN: 978-1-4939-2681-7
eBook Packages: Springer Protocols